View Older Stories View More Recent Stories
-
Citi Reiterates Neutral Rating on Pfizer (PFE)
-
Citi on Pfizer (PFE)
-
Pfizer sells entire Haleon stake for $3.24 billion
-
Midday movers: Intel, Pfizer rise; Apple falls
-
Pfizer (PFE) PT Raised to $30 at Citi
-
Pfizer (PFE) Appoints Cyrus Taraporevala to its Board
-
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
-
Pfizer (PFE) Appoints Andrew Baum as Chief Strategy and Innovation Officer
-
Pfizer Announces New Chief Strategy and Innovation Officer
-
Midday movers: GM advances, Apple declines, and more
-
This stock is a new preferred major pharma pick at Citi
-
Citi sees attractive buying opportunity in this beaten-down big pharma stock
-
Pfizer (PFE) PT Lowered to $28 at Citi, Matches Street-Low PT, Opens 90-Day Upside Catalyst Watch
-
Pfizer shares sink after it resets 2024 COVID expectations
-
Ideaya Biosciences (IDYA) Mentioned Positively at Citi, 'developing into an attractive takeout candidate'
-
Roche to acquire Telavant from Roivant and Pfizer for $7.25 billion
-
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Citi boosts SPX target
-
Pfizer (PFE) Prices $31B Debt Offering
-
Pfizer to raise $31 billion for Seagen takeover in largest debt offering
-
Pfizer Prices $31,000,000,000 Debt Offering
-
Pfizer (PFE) Announces Proposed Notes Offering
-
Pfizer Announces Proposed Notes Offering
-
Uber, Pfizer, Marriott rise premarket; Tesla, Chegg fall
-
Pfizer leans on COVID products to top estimates
-
Wells Fargo, First Republic and Pfizer fall premarket; Seagen and Boeing rise
-
Seagen, Union Pacific and Tesla rise premarket; Pfizer falls
-
Today’s most important price target changes
-
Pfizer sees steep 2023 fall in COVID sales, aims to bolster pipeline
-
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
-
Pfizer leaves COVID product forecast unchanged, shares fall
-
Pre-Open Stock Movers 06/21: Kellogg Gains on Plans to Split in Three, Tech Stocks Rebound (more...)
-
Citi Reiterates $90 PT on Bristol-Myers Squibb Co. (BMY), 'We expect some FTC scrutiny...but given the Pfizer/ Arena outcome, we remain hopeful'
-
Pfizer keeps COVID sales forecast unchanged as pandemic curbs ease
-
Moderna (MRNA) Shares Rally 11% on 'Nu' Concerns, Analyst Sees mRNA Technology Adapting Much Quicker to New COVID Variant
-
Pfizer Prices $1.0 Billion Sustainability Bond
-
Europe COVID death toll tops 300,000 as winter looms and infections surge
-
JPMorgan sees S&P 500 surging to 4,000 points in early-2021
-
Pre-Open Movers 08/25: (OVID) (GPS) (CRM) Higher; (PLCE) (POR) (PANW) Lower (more...)
-
Pfizer (PFE) PT Lowered to $37 at Citi
-
Pfizer Prices $4,000,000,000 Debt Offering
-
Elanco to become No.2 in animal health with $7.6 billion Bayer deal
-
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion
-
Citi Resumes Pfizer (PFE) at Neutral
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
-
Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources
-
Pfizer (PFE) PT Raised to $37 at Citi
-
Animal health firm Elanco surges 41 percent on debut
-
Pfizer Prices $5,000,000,000 Debt Offering
-
Pfizer (PFE) PT Raised to $34 at Citi
